{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:11:25Z","timestamp":1787166685028,"version":"build-2736575974"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T00:00:00Z","timestamp":1696896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Stevens-Johnson syndrome (SJS) is considered a hypersensitivity syndrome affecting the skin and mucous membranes. It has been reported that an anticonvulsant drug, oxcarbazepine, may cause Stevens-Johnson syndrome and toxic epidermal necrolysis (TEN). However, the clinical features of oxcarbazepine-induced Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) remain ambiguous. This article aims to explore the clinical features of SJS\/TEN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Systematic searches of several Chinese and English databases were conducted for case reports published on PubMed, EMBASE, Web of Science, MEDLINE, CNKI from January 1, 2007 to March 1, 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of seventeen patients (10 males and 7 females) were included in this study, including nine adult patients and eight pediatric patients. The results showed that males seem to have a higher prevalence of SJS\/TEN than females, and SJS\/TEN usually occurs within 2\u2009weeks after administration of oxcarbazepine (OXC). The main clinical manifestations among the included patients were rashes or maculopapules (17 cases, 100%), fever (11 cases, 64.7%), mucosal lesions (15 cases, 88.2%), conjunctivitis with\/without ocular discharge (12 cases, 70.6%), and blisters (12 cases, 70.6%). After stopping OXC or switching to other drugs that treat primary disease as well as treatment with IVIG, glucocorticoid, anti-allergy, and fluid replacement, eight of the included patients recovered completely, and another eight of the included patients reported symptomatic improvement, while the prognosis of one of the included patients was not reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Diverse clinical signs and symptoms of SJS\/TEN might result in misinterpretation and delayed diagnosis. It should be identified and treated immediately to avoid significant consequences and potentially jeopardize patients\u2019 lives.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2023.1232969","type":"journal-article","created":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T02:57:49Z","timestamp":1696906669000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Analysis of clinical features of oxcarbazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis"],"prefix":"10.3389","volume":"10","author":[{"given":"Qingzi","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renzhu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixiang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,10]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1744806920901890","DOI":"10.1177\/1744806920901890","article-title":"Trigeminal neuralgia: an overview from pathophysiology to pharmacological treatments","volume":"16","author":"Gambeta","year":"2020","journal-title":"Mol Pain"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1212\/CON.0000000000000715","article-title":"Update on antiepileptic drugs 2019","volume":"25","author":"Abou-Khalil","year":"2019","journal-title":"Continuum"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/tan.13530","article-title":"HLA-associated antiepileptic drug-induced cutaneous adverse reactions","volume":"93","author":"Mullan","year":"2019","journal-title":"HLA"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.12788\/j.sder.0058","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: clinical patterns, diagnostic considerations, etiology, and therapeutic management","volume":"33","author":"Mockenhaupt","year":"2014","journal-title":"Semin Cutan Med Surg"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s40257-015-0158-0","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: an update","volume":"16","author":"Dodiuk-Gad","year":"2015","journal-title":"Am J Clin Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/j.jid.2016.03.023","article-title":"Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in United States adults","volume":"136","author":"Hsu","year":"2016","journal-title":"J Invest Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1001\/jamadermatol.2021.1136","article-title":"Long-term physical and psychological outcomes of Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"157","author":"Hoffman","year":"2021","journal-title":"JAMA Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"omx028","DOI":"10.1093\/omcr\/omx028","article-title":"Oxcarbazepine-induced Stevens-Johnson syndrome: a pediatric case report","volume":"2017","author":"Beken","year":"2017","journal-title":"Oxf Med Case Reports"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1111\/ajd.12368","article-title":"Oxcarbazepine-induced Stevens-Johnson syndrome in a patient with HLA-B*1502 genotype","volume":"57","author":"Chen","year":"2016","journal-title":"Australas J Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/j.1468-3083.2008.02988.x","article-title":"Oxcarbazepine-induced Stevens-Johnson syndrome in a patient with HLA-B*1502 genotype","volume":"23","author":"Chen","year":"2009","journal-title":"J European Acad Dermatol Venereol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"459","DOI":"10.4103\/0253-7613.161279","article-title":"Oxcarbazepine induced toxic epidermal necrolysis \u2013 a rare case report","volume":"47","author":"Guleria","year":"2015","journal-title":"Indian J Pharmacol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"18l02304","DOI":"10.4088\/PCC.18l02304","article-title":"Oxcarbazepine-induced Stevens-Johnson syndrome","volume":"20","author":"Khalid","year":"2018","journal-title":"Prim Care Companion CNS Disord."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S1607-551X(09)70045-2","article-title":"Oxcarbazepine-induced Stevens-Johnson syndrome: a case report","volume":"25","author":"Lin","year":"2009","journal-title":"Kaohsiung J Med Sci"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s00228-016-2066-5","article-title":"Carbamazepine and oxcarbazepine: reflections after an oxcarbazepine-induced Stevens-Johnson syndrome\/toxic epidermal necrolysis overlap","volume":"72","author":"Poletti-Jabbour","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.aller.2013.12.008","article-title":"Use of intravenous immunoglobulin for Stevens-Johnson syndrome and toxic epidermal necrolysis in children: report of two cases secondary to anticonvulsants","volume":"43","author":"Romero-Tapia","year":"2015","journal-title":"Allergol Immunopathol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4103\/2229-5178.79861","article-title":"Oxcarbazepine-induced Stevens Johnson syndrome: a rare case report","volume":"2","author":"Sharma","year":"2011","journal-title":"Indian Dermatol Online J"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"42","DOI":"10.4103\/0976-0105.195130","article-title":"Antiepileptic drugs-induced Stevens-Johnson syndrome: a case series","volume":"8","author":"Trivedi","year":"2016","journal-title":"J Basic Clin Pharm"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"173","DOI":"10.4103\/0972-5229.84904","article-title":"Genetic predisposition to oxcarbazepine induced Stevens-Johnson syndrome","volume":"15","author":"Wal","year":"2011","journal-title":"Indian J Crit Care Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"365","DOI":"10.19845\/j.cnki.zfysjjbzz.2014.04.026","article-title":"Oxcarbazepine induced Stevens-Johnson syndrome in children: a case report","volume":"31","author":"Liang","year":"2014","journal-title":"J Apoplexy Nervous Dis"},{"key":"ref20","first-page":"120","article-title":"Oxcarbazepine induced Stevens-Johnson syndrome: 1 case report. Proceedings of the 2011 National Symposium on Allergic Reactions of the Chinese Medical Association","author":"Jia","year":"2011"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3969\/J.ISSN.1007-6611.2013.06.023","article-title":"Oxcarbazepine-induced Stevens-Johnson syndrome: a case report","volume":"44","author":"Wang","year":"2013","journal-title":"J Shanxi Med Univ"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"131","DOI":"10.19960\/j.cnki.issn1005-0698.2018.02.013","article-title":"Pharmacists participated in the treatment of oxcarbazepine induced Steven-Johnson syndrome in children: a case report","volume":"27","author":"Xin","year":"2018","journal-title":"J Pharmacoepidemiol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"54","DOI":"10.19542\/j.cnki.1006-5180.007047","article-title":"Oxcarbazepine-induced Stevens-Johnson syndrome: a case report","volume":"30","author":"Tian","year":"2023","journal-title":"Chin J Rural Med Pharm"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"e14273","DOI":"10.1111\/ijcp.14273","article-title":"Assessing carbamazepine and oxcarbazepine-associated Stevens-Johnson syndrome\/toxic epidermal necrolysis: data mining the public version of the FDA adverse event reporting system","volume":"75","author":"Xu","year":"2021","journal-title":"Int J Clin Pract"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1111\/epi.13925","article-title":"The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptic drugs","volume":"58","author":"Frey","year":"2017","journal-title":"Epilepsia"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/ijd.15144","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis associated with the use of macrolide antibiotics: a review of published cases","volume":"60","author":"Pejcic","year":"2021","journal-title":"Int J Dermatol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.jaad.2014.07.016","article-title":"Retrospective review of Stevens-Johnson syndrome\/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine","volume":"71","author":"Kirchhof","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.jaad.2015.07.017","article-title":"Acute generalized exanthematous pustulosis (AGEP): a review and update","volume":"73","author":"Szatkowski","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"693.e1\u201314; quiz 706\u2013708","DOI":"10.1016\/j.jaad.2013.01.033","article-title":"DRESS syndrome: part I. Clinical perspectives","volume":"68","author":"Husain","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"187.e1\u201316; quiz 203\u2013204","DOI":"10.1016\/j.jaad.2013.05.002","article-title":"Toxic epidermal necrolysis: part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment","volume":"69","author":"Schwartz","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.pharep.2014.11.009","article-title":"Antiepileptic drugs and adverse skin reactions: an update","volume":"67","author":"B\u0142aszczyk","year":"2015","journal-title":"Pharmacol Rep"},{"key":"ref32","first-page":"322","article-title":"DRESS syndrome: clinical myths and pearls","volume":"102","author":"Isaacs","year":"2018","journal-title":"Cutis"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1111\/ijd.14411","article-title":"Valproic acid and Stevens-Johnson syndrome: a systematic review of descriptive studies","volume":"58","author":"Rashid","year":"2019","journal-title":"Int J Dermatol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s12016-017-8654-z","article-title":"Current perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"54","author":"Lerch","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.jaci.2004.07.047","article-title":"Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells","volume":"114","author":"Nassif","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1001\/archderm.1994.01690050066011","article-title":"Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine","volume":"130","author":"Friedmann","year":"1994","journal-title":"Arch Dermatol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1053\/seiz.2000.0391","article-title":"Oxcarbazepine: a review","volume":"9","author":"Shorvon","year":"2000","journal-title":"Seizure"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jdermsci.2020.02.003","article-title":"SJS\/TEN 2019: from science to translation","volume":"98","author":"Chang","year":"2020","journal-title":"J Dermatol Sci"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/j.jaci.2011.08.013","article-title":"Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome","volume":"128","author":"Ko","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1001\/jamadermatol.2013.4114","article-title":"Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"149","author":"Tangamornsuksan","year":"2013","journal-title":"JAMA Dermatol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1212\/WNL.0000000000003453","article-title":"Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians","volume":"88","author":"Chen","year":"2017","journal-title":"Neurology"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/tpj.2013.40","article-title":"HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis","volume":"14","author":"Genin","year":"2014","journal-title":"Pharmacogenomics J"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1232969\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T02:57:57Z","timestamp":1696906677000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1232969\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,10]]},"references-count":43,"alternative-id":["10.3389\/fmed.2023.1232969"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1232969","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,10]]},"article-number":"1232969"}}